Cyclin D as a therapeutic target in cancer
The DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
Abstract
Cyclin D1, and to a lesser extent the other D-type cyclins, is frequently deregulated in cancer and is a biomarker of cancer phenotype and disease progression. The ability of these cyclins to activate the cyclin-dependent kinases (CDKs) CDK4 and CDK6 is the most extensively documented mechanism for their oncogenic actions and provides an attractive therapeutic target. Is this an effective means of targeting the cyclin D oncogenes, and how might the patient subgroups that are most likely to benefit be identified?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Failure to modify cyclin D1 on T286 leads to aberrant nuclear accumulation of the protein, premature S phase entry, and enhanced cellular proliferation that drives tumorigenesis (17).”
From A genome-wide screen reveals that Dyrk1A kinase promotes nucleotide excision repair by preventing aberrant overexpression of cyclin D1 and p21 (2023) · cites this paper as [17]
In the citing paper
“Possibly, CCND1 amplification and CDKN2A loss may contribute to determining response to letrozole alone”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [68]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“The deregulation of cyclin expression or CDK activation can directly lead to some of the hallmarks of cance”
BackgroundComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115 · cited 1×
“A second well-described non-catalytic role of cyclin D is the sequestration of p21 and p27 by cyclin D–CDK4/CDK6, leading to the indirect activation of CDK2 (REF”
BackgroundIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 1×
“It may also be possible to identify low-molecular-mass inhibitors of cyclin–CDK substrate interactions using high-throughput screens that are similar to those used for the discovery and preclinical testing of inhibitors of MDM2–p53 binding (nutlins”
MethodThe landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“by causing proliferation that is independent of normal extracellular cues, or by over-riding checkpoints that ensure genomic integrity and stabilit”
BackgroundFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387 · cited 1×
“Given the increasingly routine clinical use of specific kinase inhibitor”
BackgroundmTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322 · cited 1×
“In Phase II clinical trials mTOR inhibitors were particularly effective in MCL, which is characterized by almost universal overexpression of cyclin D1, although this may not be accompanied by a reduction in cyclin D1 expression (reviewed in REF”
BackgroundBiological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
Self-citation
Cited by
Items 701–800 of 1,000
Functional characterization of TcCYC2 cyclin from Trypanosoma cruzi
Potenza, M., Schenkman, S., Laverrière, M., & Téllez-Iñón, M. T. (2012) · Experimental Parasitology · doi:10.1016/j.exppara.2012.09.002 · Cited by 18
Cheng, Y., Zhang, Y., Yuan, Y., Wang, J., Liu, K., Yu, B., Xie, L., Ou-Yang, C., Wu, L., & Ye, X. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2020.609405 · Cited by 18
The Hippo pathway and its correlation with acute kidney injury
Zhang, C., 上海交通大学附属第一人民医院肾内科, 上. 2., Li, C., Xu, K., Zheng, Z., Cheng, G., Wu, H., Liu, J., & 复旦大学基础医学院病理科, 上. 2. (2022) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2022.110 · Cited by 21
“Cyclin D can induce the phosphorylation of the retinoblastoma protein (Rb), thus activating cyclin-dependent kinase (CDK) 4 and 6, which are important for G1 to S transition during cell proliferation (Hamilton & Infante, 2016; Musgrove et al., 2011).”
BackgroundLin, Z., Sheng, H., You, C., Cai, M. M., Zhang, Y., Yu, L. S., Yu, X., Lin, J. J., & Zhang, N. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3969 · Cited by 18
“This protein is regulated by a complex system of signal transduction pathways (12,13).”
Liu, T., Zeng, X., Sun, F., Hou, H., Guan, Y., Guo, D., Hou-xi, A., Wang, W., & Zhang, G. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000459693 · Cited by 18
Dinicola, S., Masiello, M. G., Proietti, S., Coluccia, P., Fabrizi, G., Palombo, A., Micciulla, F., Bistarelli, S., Ricci, G., Catizone, A., et al. (2015) · Toxicology in Vitro · doi:10.1016/j.tiv.2015.05.006 · Cited by 18
Wang, C., Zheng, P., Adeniran, S. O., Ma, M., Huang, F., Adegoke, E. O., & Zhang, G. (2019) · Theriogenology · doi:10.1016/j.theriogenology.2019.04.025 · Cited by 18
CDK4/RB/E2Fs axis as potential therapeutic target of endometrial cancer
Hu, J., Shen, J., & Sun, J. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109870 · Cited by 18
Xue, Y., Zhu, X., Meehan, B., Venneti, S., Martínez, D., Morin, G., Maïga, R. I., Chen, H., Papadakis, A. I., Johnson, R. M., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5493 · Cited by 18
“Forced SMARCB1 expression in an abdomenderived MRT cell line MON was shown to result in cell cycle arrest by repressing transcription of CCND1 encoding cyclin D1 [15], which activates CDK4/6, thereby promoting cell cycle progression [16].”
BackgroundHu, X., Wang, L., Zhang, L., & Zhang, T. (2020) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22550 · Cited by 18
Komini, C., Theohari, I., Lambrianidou, A., Nakopoulou, L., & Trangas, T. T. (2021) · Journal of Cell Science · doi:10.1242/jcs.252304 · Cited by 20
Surien, O., Ghazali, A. R., & Masre, S. F. (2021) · Scientific Reports · doi:10.1038/s41598-021-94508-7 · Cited by 19
Asuthkar, S., Venkataraman, S., Janardhan, A., Shishido, K., Vibhakar, R., Veo, B. L., Purvis, I. J., Guda, M. R., & Velpula, K. K. (2022) · Cancers · doi:10.3390/cancers14071673 · Cited by 19
Kocatürk, B., Tieken, C., Vreeken, D., Ünlü, B., Engels, C. C., de Kruijf, E. M., Kuppen, P. J. K., Reitsma, P. H., Bogdanov, V. Y., & Versteeg, H. H. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13049 · Cited by 19
Semprebon, S. C., Marques, L. A., D’Epiro, G. F. R., de Camargo, E. A., da Silva, G. N., Niwa, A. M., Macedo, F., & Mantovani, M. S. (2015) · Toxicology in Vitro · doi:10.1016/j.tiv.2015.10.012 · Cited by 20
“Thus, cyclin D is partially responsible for the excessive proliferation of cancer cells in many human cancers and is therefore a good target for the development of anticancer drugs (Musgrove et al., 2011).”
BackgroundWu, G., FAN, H., Huang, Y., Zheng, C., Ye, J., & Liu, X. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2527 · Cited by 18
Anti-tumour effect of metformin in canine mammary gland tumour cells
Saeki, K., Watanabe, M., Tsuboi, M., Sugano, S., Yoshitake, R., Tanaka, Y., Ong, S. M., Saito, T., Matsumoto, K., Fujita, N., et al. (2015) · The Veterinary Journal · doi:10.1016/j.tvjl.2015.04.026 · Cited by 20
Iizuka, S., Oridate, N., Nashimoto, M., Fukuda, S., & Tamura, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114121 · Cited by 22
“Patients with HNSCC OPEN ACCESS Citation: Iizuka S, Oridate N, Nashimoto M, Fukuda S, Tamura M (2014) Growth Inhibition of Head and Neck Squamous Cell Carcinoma Cells by sgRNA Targeting the Cyclin D1 mRNA Based on TRUE Gene Silencing.”
BackgroundInfluentialLee, M., Hsieh, N., Huang, C., & Li, C. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25285 · Cited by 18
“Cyclin D1 is often upregulated in cancer (Musgrove et al., 2011), and our laboratory has recently reported that MED28 regulates cyclin D1 expression in human breast cancer cells (Huang et al., 2015).”
BackgroundGrillier‐Vuissoz, I., & Mazerbourg, S. (2012) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.s8-002 · Cited by 21
“Cyclin D1 is a major regulator of cell cycle progression and triggers a multitude of proliferative and transforming signaling pathways [77].”
BackgroundSerpeloni, J. M., Specian, A. F. L., Ribeiro, D. L., Benício, L. M., Nunes, H., Franchi, L., Rocha, C., Vilegas, W., Varanda, E. A., & Cólus, I. (2019) · Human & Experimental Toxicology · doi:10.1177/0960327119888261 · Cited by 21
“Its ability to activate CDKs is its main mechanism of oncogenic activity.(48) Overexpression of CCND1 tends to cause a rapid transition from G1 phase to S phase in normal fibroblasts,(49) corroborated by our cell cycle kinetic results, where only normal cells treated with DXR showed decreased G1 population.”
BackgroundKnockdown of circ-TTBK2 Inhibits Glioma Progression by Regulating miR-1283 and CHD1
Han, C., Wang, S., Wang, H., & Zhang, J. (2020) · Cancer Management and Research · doi:10.2147/cmar.s252916 · Cited by 18
“Cyclin D1 is a key biomarker for cell proliferation, which could activate CDK4 to regulate the G1-to-S-phase transition.(19,20) E-cadherin is a representative epithelial surface marker and Vimentin is an important mesenchymal marker; the loss of E-cadherin during epithelial-to-mesenchymal transition is mediated via th…”
BackgroundMontero‐Hidalgo, A. J., Pérez‐Gómez, J. M., Martínez‐Fuentes, A. J., Gómez‐Gómez, E., Gahete, M. D., Jiménez‐Vacas, J. M., & Luque, R. M. (2022) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1760 · Cited by 19
“3.3.5 | CCND1b SVs CCND1 regulates the transition from G1 to S cell cycle phases through the modulation of CDK4 and CDK6 activity (Musgrove et al., 2011; Qie & Diehl, 2016).”
BackgroundInfluentialGe, Y., Janson, V., & Liu, H. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.136820 · Cited by 19
Hong, Y., Wang, Y., Shu, W., Li, J., Mi, Y., Chen, H., & Chen, C. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102835 · Cited by 20
Ma, J., Cui, B., Ding, X., Wei, J., & Cui, L. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1635-9 · Cited by 20
“Cyclin D1 executes the transcriptional regulation through its interaction with transcriptional factors and chromatin modifiers [7, 8].”
BackgroundAnti-tumor effects of bemiparin in HepG2 and MIA PaCa-2 cells
Alur, İ., Dodurga, Y., Seçme, M., Elmas, L., Bağcı, G., Gökşin, İ., & Avcı, Ç. B. (2016) · Gene · doi:10.1016/j.gene.2016.03.044 · Cited by 17
Harris, A. L., Lee, S. E., Dawson, L. K., Marlow, L. A., Edenfield, B. H., Durham, W. F., Flotte, T. J., Thompson, M. A., Small, D. L., Synnott, A. J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23649 · Cited by 17
“Currently, estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)negative status in breast cancer patients is the only used predictive biomarker for response to CDK4/6 inhibition [39, 40].”
BackgroundEsmaeili‐Mahani, S., Samandari-Bahraseman, M. R., & Yaghoobi, M. M. (2018) · Europe PMC (PubMed Central) · Cited by 17
Guo, Q., Lin, X., Ye, L., Xu, R., Dai, Y., Zhang, Y., & Chen, Q. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00633-9 · Cited by 17
Combination of MCM2 With Ki67 and p16 Immunohistochemistry Can Distinguish Uterine Leiomyosarcomas
Keyhanian, K., Lage, J. M., Chernetsova, E., Sekhon, H. S., Eslami, Z., & Islam, S. (2019) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000616 · Cited by 17
“Cancer-associated mutations also occur and both nuclear and cytoplasmic localizations are reported in different malignancies following mutation (28).”
BackgroundDiscovery of Dihydropyrrol-2-ones as Novel G0/G1-Phase Arresting Agents Inducing Apoptosis
Yang, D., Huang, C., Liao, H., Zhang, H., Wu, S., Zhu, Q., & Zhou, Z. (2019) · ACS Omega · doi:10.1021/acsomega.9b02543 · Cited by 17
The PDE4 inhibitor CHF6001 affects keratinocyte proliferation via cellular redox pathways
Woodby, B. L., Sticozzi, C., Pambianchi, E., Villetti, G., Civelli, M., Valacchi, G., & Facchinetti, F. (2020) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2020.108355 · Cited by 18
Cleistanthin A induces apoptosis and suppresses motility of colorectal cancer cells
Jearawuttanakul, K., Khumkhrong, P., Suksen, K., Reabroi, S., Munyoo, B., Tuchinda, P., Borwornpinyo, S., Boonmuen, N., & Chairoungdua, A. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173604 · Cited by 17
Guo, M., Liu, Z., Si, J., Zhang, J., Zhao, J., Guo, Z., Xie, Y., Zhang, H., & Gan, L. (2021) · BioMed Research International · doi:10.1155/2021/5582648 · Cited by 18
Inhibiting CDK4/6 in pancreatic ductal adenocarcinoma via microRNA-21
Mortoglou, M., Miralles, F., Mould, R. R., Sengupta, D., & Onganer, P. U. (2023) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2023.151318 · Cited by 18
FHL1 inhibits the growth of tongue squamous cell carcinoma cells via G1/S cell cycle arrest
REN, W., LIAN, P., Cheng, L., Du, P., Guan, X., Wang, H., Ding, L., Gao, Z.-Y., Huang, X. Y., Xiao, F., et al. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3844 · Cited by 17
“Overexpression of cyclin D is common in human cancers of epithelial cell origin (20).”
Expression Analysis of Genes Involved in the RB/E2F Pathway in Astrocytic Tumors
Ferreira, W. A. S., Araújo, M. D., Anselmo, N. P., de Oliveira, E. H. C., Brito, J. R. N., Burbano, R. M. R., Harada, M. L., & Borges, B. D. N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137259 · Cited by 17
“In tumors, many studies have reported that this gene may undergo amplification, rearrangements, and overexpression or undergo methylation in the promoter region [6, 64, 106, 107].”
BackgroundMicroenvironmental Control of the Breast Cancer Cell Cycle
Guo, X., Wu, Y., Hathaway, H. J., & Hartley, R. S. (2012) · The Anatomical Record · doi:10.1002/ar.22417 · Cited by 18
“Active cyclin D-cdk4/6 phosphorylates the G1 checkpoint protein Rb, resulting in the release of E2F, a transcription factor sequestered and inhibited by Rb (Musgrove et al., 2011).”
BackgroundAnti-Tumorigenic Effects of Capsaicin in Colon Cancer
Lee, S., & Clark, R. (2016) · Journal of Food Chemistry and Nanotechnology · doi:10.17756/jfcn.2016-025 · Cited by 18
“Cyclin D1 and cyclin D3 are the major form of D type cyclins and play a significant role in the transition of the cell cycle from the G1 to S phase in collaboration with partner proteins, such as CDK4/6 (cyclin-dependent kinases 4/6) [20].”
BackgroundInfluentialChen, H., Guan, Y., Baek, S. J., & Zhong, Q. (2018) · Food Biophysics · doi:10.1007/s11483-018-9559-y · Cited by 17
Fu, Y., Wang, Z., Luo, C., Wang, Y., Wang, Y., Zhong, X., & Zheng, H. Y. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.12.005 · Cited by 19
Gao, F., Zhou, L. Q., Li, M., Liu, W., Yang, S., & Li, W. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s251295 · Cited by 17
Smith, C. C., Viny, A. D., Massi, E., Kandoth, C., Socci, N. D., Rapaport, F., Najm, M., Medina-Martinez, J. S., Papaemmanuil, E., Tarver, T. C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3458 · Cited by 18
The pathophyiological role of aminoacyl-tRNA synthetases in digestive system diseases
Wusiman, W., Zhang, Z., Ding, Q., & Liu, M. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.935576 · Cited by 16
“MRS stabilizes CDK4 (cyclin-dependent kinase4), promotes G1-to-S cell cycle transition, and enhances the tumorigenic ability of cancer cells, and this effect is much more obvious in cancers that are deficient in p16INK4a, which blocks the function of CDK4, thereby suppressing cell cycling (Musgrove et al., 2011; Kwon…”
BackgroundJalili, C., shamsi, R. R., Amiri, B., Kakebaraie, S., Jalili, F., & Nasta, T. Z. (2024) · Toxicology · doi:10.1016/j.tox.2024.153773 · Cited by 17
F-box protein FBXO32 ubiquitinates and stabilizes D-type cyclins to drive cancer progression
Li, F., Yu, H., Zhang, Y., Ma, Y., Chen, X., Zhang, J., Sun, L., Guo, R., Wu, Y., Zheng, P., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59407-9 · Cited by 19
Plasmacytomagenesis in Eμ-v-abl transgenic mice is accelerated when apoptosis is restrained
Vandenberg, C. J., Waring, P., Strasser, A., & Cory, S. (2014) · Blood · doi:10.1182/blood-2014-04-570770 · Cited by 16
DENG, Q.-F., Sun, X., Liang, Z., Zhang, Z., Yu, D., & Zhong, C. (2016) · Oncology Reports · doi:10.3892/or.2016.4623 · Cited by 16
Liang, M., Hsieh, T., Liu, Y., Chen, Y., Lee, Y., Chang, F., Lin, S., Huang, M., Ho, D. M., Wong, T., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23509 · Cited by 16
“In the analysis of a large group of pediatric embryonal brain tumors including medulloblastoma and supratentorial neuroectodermal tumor (sPNET), CDK6 and CCND1 gene amplification are more commonly observed in sPNET (25%)[29].”
BackgroundXia, L., Li, S., Liu, Y., Huang, Y., Ni, B., Wan, L., Mei, H., Li, X., Cai, Z., & Li, Z. (2019) · Oncology Letters · doi:10.3892/ol.2019.9937 · Cited by 18
Traces of intact paraben molecules in endometrial carcinoma
Doğan, S., Tongur, T., ERKAYMAZ, T., Erdoğan, G., Ünal, B., Şık, B., & Şimşek, T. (2019) · Environmental Science and Pollution Research · doi:10.1007/s11356-019-06228-1 · Cited by 17
Chen, X., Yue, W., Lin, T., Li, N., Chen, Y., Zhang, L., & Chen, J. (2021) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-021-03301-6 · Cited by 18
Valdez, L., Cheng, B., Gonzalez, D., Rodriguez, R., Campano, P., Tsin, A. T. C., & Fang, X. (2022) · Oncotarget · doi:10.18632/oncotarget.28227 · Cited by 16
Skolastika, S., Hanif, N., Ikawati, M., & Hermawan, A. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/4172531 · Cited by 17
“Cyclin D1, encoded by CCND1, is considered an oncogene that promotes cell proliferation, growth, angiogenesis, and resistance to chemotherapy and radiotherapy [43, 44].”
BackgroundA novel role for the cell cycle regulatory complex cyclin D1– CDK 4 in gluconeogenesis
Hosooka, T., & Ogawa, W. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12369 · Cited by 18
Salisbury, T. B., Morris, G. Z., Tomblin, J. K., Chaudhry, A. R., Cook, C. R., & Santanam, N. (2013) · ISRN Endocrinology · doi:10.1155/2013/104850 · Cited by 17
“CCND1 is a regulatory protein that activates the cell cycle, increases cell proliferation, and has been implicated as a promoter of breast tumorigenesis [13].”
BackgroundTabarestani, S., Ghaderian, S. M. H., Rezvani, H., Mirfakhraie, R., Ebrahimi, A., Attarian, H., Raafat, J., Ghadyani, M., Alavi, H. A., Kamalian, N., et al. (2014) · Cellular Oncology · doi:10.1007/s13402-013-0165-1 · Cited by 16
Reikvam, H., Hauge, M., Brenner, A. K., Hatfield, K. J., & Bruserud, Ø. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1032935 · Cited by 17
Deng, L., Xiang, X., Yang, F., Xiao, D., Liu, K., Chen, Z., Zhang, R., & Feng, G. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.06.016 · Cited by 16
“Importantly, cyclin D1 overexpression leads to unco ntr lled cell proliferation and is linked to the development, progression, poor progno sis, and chemoresistance of a broad range of human malignancies[16][17].”
BackgroundNeuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma
Davidson, B., Hellesylt, E., Holth, A., Danielsen, H. E., Skeie-Jensen, T., & Katz, B. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2172-5 · Cited by 16
“Cyclin D binding to CDK4 and CDK6 results in phosphorylation of several proteins, including the retinoblastoma protein, mediating cell cycle progression [9].”
BackgroundVg, D. R., Sinto, M. S., Thomas, S., & Kannan, S. (2018) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.188295 · Cited by 16
MMP24 as a Target of YAP Is a Potential Prognostic Factor in Cancer Patients
Sugimoto, W., Itoh, K., Hirata, H., Abe, Y., Torii, T., Mitsui, Y., Budirahardja, Y., Tanaka, N., & Kawauchi, K. (2020) · Bioengineering · doi:10.3390/bioengineering7010018 · Cited by 16
Abemaciclib, A Selective CDK4/6 Inhibitor, Restricts the Growth of Pediatric Ependymomas
Liang, M., Chen, C., Liu, Y., Huang, M., Lin, Y., Wong, T., Lin, S., Chu, S.-S., Ding, Y.-H., & Hsieh, T. (2020) · Cancers · doi:10.3390/cancers12123597 · Cited by 16
“Studies have shown that amplification or overexpression of cyclin D1 and CDK4/6 occurs in several tumors, such as glioma, melanoma, head and neck cancers, non–small-cell lung cancer, and breast cancer [10,11].”
BackgroundAcyldepsipeptides inhibit the growth of renal cancer cells through G1 phase cell cycle arrest
Xu, S., Guo, P., Gao, Y., Shi, Q., He, D., Gao, Y., & Zhang, H. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.07.119 · Cited by 16
Discovery of HyT‐Based Degraders of CDK9‐Cyclin T1 Complex
Lin, R., Yang, J., Liu, T., Wang, M., Ke, C., Luo, C., Lin, J. H., Li, J., & Lin, H. (2023) · Chemistry & Biodiversity · doi:10.1002/cbdv.202300769 · Cited by 16
Abdulkareem, S. J., Jafari-Gharabaghlou, D., Jadid, M. F. S., Salmani-Javan, E., Toroghi, F., & Zarghami, N. (2024) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-023-00495-7 · Cited by 16
“Cyclins and CDKs blockers have recently been reported to be helpful in preventing tumor cell proliferation, inducing an aging-like phenotype, and affecting cellular metabolism [46, 47].”
El‐Fakharany, E. M., Elsharkawy, W. B., El‐Maradny, Y. A., & El‐Gendi, H. (2024) · Journal of Food Science · doi:10.1111/1750-3841.17223 · Cited by 18
Honda, A., Valogne, Y., Nader, M. B., Bréchot, C., & Faivre, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039249 · Cited by 15
“Evidence concerning the role of cyclins D and E in human carcinogenesis has accumulated [39], [40].”
BackgroundZhang, X., Sukamporn, P., Zhang, S., Min, K., & Baek, S. J. (2017) · Oncology Reports · doi:10.3892/or.2017.5693 · Cited by 15
Rossi, L. A., McCartney, A., Risi, E., Santo, I. D., Migliaccio, I., Malorni, L., Biganzoli, L., & Leo, A. D. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.05.019 · Cited by 15
Chonsut, P., Mahalapbutr, P., Pradubyat, N., Chavasiri, W., Wonganan, P., & Ketchart, W. (2019) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13176 · Cited by 15
“CCND1 is involved in cancer cell proliferation.([14]) NCoA3 is the ER coactivator that assists the transcription of ER-targeted genes.”
BackgroundA Cyclin D1–Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma
Demajo, S., Alberó, R., Clot, G., Castellano, G., Navarro, A., Capdevila, C., Enjuanes, A., Nadeu, F., Giné, E., Pinyol, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2868 · Cited by 16
“colorectal cancer, and activating point mutations are present in esophageal and endometrial carcinomas (15).”
BackgroundSynthesis and Clinical Development of Palbociclib: An Overview
Konar, D., Maru, S., Kar, S., & Kumar, K. (2020) · Medicinal Chemistry · doi:10.2174/1573406417666201204161243 · Cited by 15
Cardiac complications of cancer therapies
Mauro, A. G., Hunter, K., & Salloum, F. N. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2022.03.006 · Cited by 22
Zhao, W., Liu, L., Li, X., & Xu, S. Q. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109031 · Cited by 18
Yang, Q., Zhu, W., & Gong, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148483 · Cited by 15
“CDK 4/6 phosphorylate and inactivate retinoblastoma protein and subsequently negatively control e2f (49, 50).”
BackgroundTargeting cyclin D1 as a therapeutic approach for papillary thyroid carcinoma
Cai, W. L., Shu, L.-Z., Liu, D.-J., Zhou, L., Wang, M.-M., & Deng, H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1145082 · Cited by 16
“However, targeting cyclin D1 is often considered difficult because of its lack of intrinsic enzymatic activity (11).”
BackgroundInfluentialCyclin D1 harboring the T286I mutation promotes oncogenic activation in endometrial cancer
Ikeda, Y., Oda, K., Wada‐Hiraike, O., Koso, T., Miyasaka, A., Kashiyama, T., Tanikawa, M., Sone, K., Nagasaka, K., Maeda, D., et al. (2013) · Oncology Reports · doi:10.3892/or.2013.2515 · Cited by 17
Li, M., Xin, X., Wu, T., Teng, H., Wang, H., & Wang, H. (2015) · Tumor Biology · doi:10.1007/s13277-015-3309-2 · Cited by 17
“in various types of human cancers, including bladder, lung, and breast cancer [33].”
BackgroundYe, J., Li, L., Feng, P., Wan, J., & Li, J. (2016) · Oncology Reports · doi:10.3892/or.2016.4823 · Cited by 15
“Furthermore, we identified CCND1, a putative therapeutic target oncogene (25), as a direct and functional target of miR-34a by binding to the specific 3'-UTR of CCND1.”
BackgroundInfluentialGiuliano, A., Swift, R., Arthurs, C., Marote, G., Abramo, F., McKay, J., Thomson, C., Beltrán, M., Millar, M., Priestnall, S. L., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161103 · Cited by 18
“Gene amplification or over-expression of CD1 protein has been demonstrated in many human cancers including head and neck, breast and colon (see [56] for a review).”
BackgroundCarlson, J. A., Xavier‐Júnior, J. C. C., Tarasen, A. J., Sheehan, C. E., Otto, G. A., Miller, V. A., Stephens, P. J., Elvin, J. A., Vergilio, J., Suh, J. H., et al. (2016) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000000729 · Cited by 16
“CDK4 and its functional homolog CDK6 are activated by D-type cyclins and promote cell cycle progression by inactivating the retinoblastoma tumor suppressor protein (Rb).(91,92)”
BackgroundCyclin D1 in the Liver: Role of Noncanonical Signaling in Liver Steatosis and Hormone Regulation.
Núñez, K., Gonzalez-Rosario, J., Thevenot, P., & Cohen, A. J. (2017) · PubMed · Cited by 15
Chai, Y., & Zhao, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-04417-x · Cited by 16
SMER28 Attenuates PI3K/mTOR Signaling by Direct Inhibition of PI3K p110 Delta
Kirchenwitz, M., Stahnke, S., Prettin, S., Borowiak, M., Menke, L., Sieben, C., Birchmeier, C., Rottner, K., Stradal, T. E. B., & Steffen, A. (2022) · Cells · doi:10.3390/cells11101648 · Cited by 16
“CDK4/6 heterodimerize with D cyclins to form active kinase complexes allowing cell cycle progression from G1 to S, while the activity of these kinase complexes is inhibited by the association of p27/Kip and p21 Waf1/Cip1 with CDKs and cyclins through the formation of heterotrimeric complexes [34].”
BackgroundGeorgiadou, D., Sergentanis, T. Ν., Sakellariou, S., Filippakis, G. M., Zagouri, F., Vlachodimitropoulos, D. G., Ψαλτοπούλου, Θ., Lazaris, A. C., Patsouris, E., & Zografos, G. (2014) · Apmis · doi:10.1111/apm.12289 · Cited by 16
“such as lung cancer, melanoma, breast cancer and pancreatic cancer, head and neck squamous cell carcinoma and mantle cell lymphoma (3).”
BackgroundSynergistic anticancer effect by targeting CDK2 and EGFR–ERK signaling
Wu, J., Chen, Y., Li, R., Guan, Y., Chen, M. H., Yin, H., Yang, X., Jin, M., Huang, B., Ding, X., et al. (2023) · The Journal of Cell Biology · doi:10.1083/jcb.202203005 · Cited by 18
“CDK4/6 and CDK1/2 are commonly dysregulated in various types of cancers (Musgrove et al., 2011; Otto and Sicinski, 2017).”
Bergman, M. T., Zhang, W., Liu, Y., Jang, H., & Nussinov, R. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c03243 · Cited by 15
Segment- and cell-specific expression of D-type cyclins in the postnatal mouse epididymis
Wang, H., & Kumar, T. R. (2012) · Gene Expression Patterns · doi:10.1016/j.gep.2012.01.003 · Cited by 21
“The D-type cyclins, cyclin D1, D2 and D3 are critical regulators of the G1-S phase transition of cell cycle (Coudreuse and Nurse, 2010; Hengstschlager et al., 1999; Ikushima and Miyazono, 2010; Malumbres and Barbacid, 2009; Molinari, 2000; Musgrove et al., 2011; Nakayama et al., 2001; Sherr, 2000; Turner and Grose, 20…”
InfluentialOhta, S., Tago, K., Funakoshi‐Tago, M., Matsugi, J., & Yanagisawa, K. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.04.013 · Cited by 14
Wu, Y., Tang, W., Cao, Y., Jiang, D., Zhao, L., Zhao, J., Zhang, Y., Li, C., Cheng, C., Wang, S., et al. (2020) · Biotechnology Journal · doi:10.1002/biot.201900430 · Cited by 15
Cao, D., Wu, S., Wang, X., Li, Y., Xu, H., Pan, Z., Wu, Z., Yang, L., Tan, X., & Li, D. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02269-0 · Cited by 15
Anti-cancer therapy with cyclin-dependent kinase inhibitors: impact and challenges
Reinius, M., & Smyth, E. C. (2021) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2021.3 · Cited by 14
Lidocaine enhances the efficacy of palbociclib in triple-negative breast cancer.
Han, B. S., Jung, K. H., Lee, J. E., Yoon, Y., Ko, S., Park, M. S., Lee, Y. J., Kim, S. E., Cho, Y. J., Lee, P., et al. (2022) · PubMed · Cited by 16
Akt-dependent activation of Erk by cyclin D1b contributes to cell invasiveness and tumorigenicity
Kim, C. J., Tambe, Y., Mukaisho, K., Sugihara, H., Kawauchi, A., & Inoue, H. (2016) · Oncology Letters · doi:10.3892/ol.2016.5286 · Cited by 14
“Although expression of cyclin D1b is barely detectable in normal tissue, it has been detected in various types of cancer, including bladder cancer, esophageal cancer, colon cancer, B-lymphoid malignancies, breast cancer, and prostate cancer, Ewing's sarcoma and mantle cell lymphoma (4).”
The EMSY Gene Collaborates with CCND1 in Non-Small Cell Lung Carcinogenesis
Baykara, O., Dalay, N., Bakır, B., Bulut, P., Kaynak, K., & Buyru, N. (2017) · International Journal of Medical Sciences · doi:10.7150/ijms.19355 · Cited by 14
“Despite reports on over-expression of different genes in that region, the most likely tumorigenic driver at this locus is still thought to be CCND1, which encodes cyclin D1 [25].”
BackgroundYabasin, I. B., Sanches, J. G. P., Ibrahim, M. M., Huidan, J., Walana, W., Lu, Z., & Wen, Q. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00941 · Cited by 17
Current Knowledge in Genetics, Molecular Diagnostic Tools, and Treatments for Mantle Cell Lymphomas
Sethi, S., Epstein-Peterson, Z. D., Kumar, A. A., & Ho, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.739441 · Cited by 14
“Although MCLs are characterized in most cases by t (11,14) (q13q32)/CCND1-IGH, other variant translocations and cryptic insertion of enhancer elements can also lead to MCL.”
BackgroundInfluentialBester, A. C., Kafri, M., Maoz, K., & Kerem, B. (2013) · Scientific Reports · doi:10.1038/srep02189 · Cited by 15
Metadata
- Authors
- Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L.
- Affiliations
- Garvan Institute of Medical Research (AU)
- Corresponding author
- Sutherland, Robert L.
- ORCID
- Caldon, C. Elizabeth
- Venue
- Nature Reviews Cancer
- Published
- 2011-07-07
- Volume
- 11
- Issue
- 8
- Pages
- 558-572
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2089655089
- Cited by
- 1,370
- References
- 190
- Citations by year
- 2026: 54 · 2025: 65 · 2024: 57 · 2023: 78 · 2022: 85 · 2021: 102 · 2020: 113 · 2019: 100 · 2018: 93 · 2017: 130 · 2016: 129 · 2015: 105 · 2014: 92 · 2013: 91 · 2012: 75
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- cyclin D1, cyclin D, cyclin-dependent kinases, CDK4, CDK6, oncogene deregulation, cancer therapy, therapeutic target, biomarkers, patient subgroup identification, tumor progression
- MeSH terms
- Humans, Neoplasms, Oncogenes, Polymorphism, Genetic, Cyclin D
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.